Research · 3 min read
What an Age Floor in an Indication Means
One GLP-1 indication names adults and patients aged 12 and older. Another, on the same label, says adults only. The ages are not a suggestion, and they are not the same question as who a seller will accept.
Key takeaways
- An age in an approved indication is part of the claim, not background to it — the approval reaches that population and no further.
- One label can carry different ages for different uses: this one's weight indication names adults and patients aged 12 and older with obesity, while its MASH indication is stated for adults.
- The pediatric clause attaches to a specific criterion inside the indication, so a summary that merges the criteria is broader than the label's own sentence.
- A seller's minimum age is a business and licensing decision, commonly higher than an indication's, and the two move independently.
- A compounded preparation carries no FDA-approved indication and therefore no approved age population — any age stated with it is the seller's own policy.
- When a page and a label disagree, the label is public, dated on its face, and reachable without going through the seller.
Answer first: the age is part of the approved claim
An FDA-approved indication states what a drug is approved to be used for and in whom. The population is not context around the claim; it is part of the claim. When an indication names an age, the approval reaches that age and no further.
The current Wegovy label shows this plainly, because different indications on the same label carry different ages. It is indicated "to reduce excess body weight and maintain weight reduction long term in: adults and pediatric patients aged 12 years and older with obesity; adults with overweight in the presence of at least one weight-related comorbid condition." A separate indication on the same label — for noncirrhotic MASH with moderate to advanced liver fibrosis — is stated for adults.
So one molecule, one label, and two different age boundaries depending on which approved use is being discussed. A sentence that says "approved down to 12" without saying approved for what has dropped the half that makes it true.
The clause is narrower than it first reads
Read the weight indication again with its own punctuation. "Adults and pediatric patients aged 12 years and older with obesity" is one population. "Adults with overweight in the presence of at least one weight-related comorbid condition" is a second, and it does not carry the pediatric clause.
That structure matters. The adolescent population appears attached to the obesity criterion, not to the overweight-with-comorbidity criterion. A summary that merges the two into "approved for 12 and up for weight loss" states something broader than the label's own sentence.
This is the general shape of an indication: a list of qualifying conditions, each with its own population, joined by semicolons that do a lot of quiet work. The semicolons are where most misquotations happen.
An age floor is not a statement about anyone in particular
An approved indication describes a population an agency judged the evidence to cover. It does not say the drug is appropriate for a given person inside that population, and it does not say anything about a person outside it beyond the fact that the approval does not reach them.
Prescribing outside an approved indication is a recognized category with its own name, and this site has a separate article on what that term does and does not mean. The point here is narrower: the existence of an age in an indication tells a reader where the approved claim stops, not where a prescriber's judgment stops, and not what any individual should do.
Nothing on this site can assess a person. A number in an indication is a fact about a document, and the decision about a patient belongs to a clinician who can see that patient's records.
What a seller's minimum age is instead
A telehealth company also states a minimum age, and it is a different kind of statement. A seller's age floor is a business and licensing decision — who the company will accept as a customer — and it is commonly higher than an indication's, often eighteen.
The two can move independently. An indication reaching a younger population does not oblige any company to serve that population, and a company raising its own minimum is not narrowing an approval. When a marketing page cites an age, the useful question is which of the two it is quoting: the label, or the company's own terms.
For a compounded preparation the question does not arise in the same form at all, because a compounded product is not an FDA-approved drug and carries no FDA-approved indication — so it has no approved age population to cite. Any age attached to such an offer is the seller's own policy.
How to check the claim on a page
Find the specific use being claimed, then find the population attached to that specific use. If a page names an age without naming which indication it belongs to, the citation is incomplete and cannot be checked.
Then check what product the page is selling. An approved indication belongs to the approved product; it does not travel to a different preparation sharing an active ingredient's name. A page that pairs an approved product's age wording with a compounded offer has borrowed authority the offer does not have.
Where a page and a label disagree, the label is the document with an agency judgment behind it — and it is public, dated on its face, and reachable without going through the seller.
Sources
- WEGOVY (semaglutide) injection — Highlights of Prescribing Information and full prescribing informationThe INDICATIONS AND USAGE wording quoted here in full, including the weight indication naming "adults and pediatric patients aged 12 years and older with obesity" and, as a separate criterion, "adults with overweight in the presence of at least one weight-related comorbid condition"; and the fact that the MASH indication on the same label is stated for adults, which is what establishes that two indications on one label carry different ages. This citation is limited to Indications and Usage; it does not support a separate assessment of the Pediatric Use section.
Frequently asked questions
Does this label's weight indication include people under 18?
Its weight indication names "adults and pediatric patients aged 12 years and older with obesity," alongside a separate criterion for adults with overweight and at least one weight-related comorbid condition. The pediatric clause appears with the obesity criterion.
Do all the indications on one label share the same ages?
No, and this label is the example. Its MASH indication — for noncirrhotic disease with moderate to advanced liver fibrosis — is stated for adults, while its weight indication reaches a younger population. Same label, different ages, different approved uses.
If an indication reaches age 12, will a telehealth company accept a 12-year-old?
That is a separate question with a separate answer. A company's minimum age is its own business and licensing decision and is frequently higher than an indication's. An approval does not oblige a company to serve anyone.
Does a compounded product have an age floor from the label?
No. A compounded preparation is not an FDA-approved drug and carries no FDA-approved indication, so there is no approved population attached to it. Any age stated with such an offer is the seller's own policy.
Why does the exact punctuation of an indication matter?
Because the population is attached to a specific criterion, not to the sentence as a whole. In this label's weight indication the pediatric clause sits with the obesity criterion; a summary that merges the criteria states something broader than the label does.
Does this article describe the label's Pediatric Use section?
No. This article explains the age boundaries in Indications and Usage. It does not assess the pediatric safety evidence or replace the separate Pediatric Use section of the prescribing information.